Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DUVOID vs CEVIMELINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective alpha-1A adrenergic receptor antagonist; relaxes smooth muscle in the bladder neck and prostate, reducing outflow resistance.
Cevimeline is a muscarinic cholinergic agonist that binds to M1 and M3 receptors, stimulating salivary gland secretion.
Benign prostatic hyperplasia (BPH) - treatment of symptoms,Off-label: None established
Treatment of dry mouth in patients with Sjögren's syndrome
100 mg orally three times daily.
30 mg orally three times daily. May increase to 60 mg three times daily if needed.
Terminal elimination half-life is 12–15 hours in patients with normal renal function; prolonged to 24 hours or more in moderate-to-severe renal impairment.
The terminal elimination half-life is approximately 3–4 hours in patients with normal renal function, supporting three-times-daily dosing.
Extensively metabolized in the liver primarily by CYP2D6 and CYP3A4, with possible minor contributions from other CYPs.
Primarily metabolized by CYP2D6 and CYP3A3/4; also undergoes CYP2C19 and CYP3A5 metabolism.
Renal elimination accounts for approximately 90% of a dose as unchanged drug; biliary/fecal excretion is minor (<10%).
Cevimeline is primarily eliminated via renal excretion (approximately 80% of the dose as unchanged drug and metabolites) and biliary/fecal excretion (approximately 20%).
Approximately 50–70% bound to plasma proteins, primarily albumin.
Approximately 20% bound to plasma proteins (mainly albumin).
Vd approximately 0.6 L/kg, indicating distribution into total body water.
Volume of distribution is approximately 1.2 L/kg, indicating extensive extravascular distribution into tissues.
Oral: 75–85% (may be decreased with food); subcutaneous: nearly 100%.
Absolute oral bioavailability is approximately 30–40% due to first-pass metabolism.
GFR 30-89 m L/min: no adjustment; GFR <30 m L/min: avoid use.
No specific adjustment required; use caution in severe renal impairment (Cr Cl <30 m L/min).
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 50 mg twice daily; Child-Pugh C: avoid use.
Child-Pugh Class A and B: No adjustment. Child-Pugh Class C: Contraindicated.
Not recommended for use in pediatric patients.
Not FDA approved for pediatric use; safety and efficacy not established.
Initial dose 50 mg twice daily; titrate cautiously due to increased anticholinergic sensitivity.
No specific dose adjustment, but consider age-related renal decline and potential for increased anticholinergic effects.
None.
None
Orthostatic hypotension (especially dose-related; syncope reported),Intraoperative floppy iris syndrome (IFIS) during cataract surgery,Priapism (rare),Dizziness, somnolence, and fatigue may occur,Use caution with hepatic impairment,Avoid use with strong CYP3A4 inhibitors or inducers
Use with caution in patients with cardiovascular disease, asthma, chronic bronchitis, COPD, cholelithiasis, nephrolithiasis, or biliary tract disorders; may cause visual disturbances including decreased visual acuity, especially at night; contraindicated in patients with uncontrolled asthma, narrow-angle glaucoma, or acute iritis.
Hypersensitivity to DUVOID or any component,Moderate to severe hepatic impairment (Child-Pugh class B or C),Use with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir)
Uncontrolled asthma,Narrow-angle glaucoma,Acute iritis
Take on an empty stomach; food may decrease absorption. Avoid alcohol as it may increase cholinergic side effects.
No significant food interactions; however, high-fat meals may delay absorption. Avoid excessive caffeine as it may exacerbate side effects like tachycardia.
DUVOID (bethanechol) is classified as FDA Pregnancy Category C. No adequate studies in pregnant women. Animal reproduction studies have not been conducted. Fetal risk cannot be ruled out. Use only if potential benefit justifies potential risk to fetus. No known specific trimester risks.
Pregnancy Category C. In animal studies, cevimeline caused reduced fetal weight and increased skeletal variations at doses 0.1 times the maximum recommended human dose. No adequate human studies. Risk cannot be ruled out; use only if benefit justifies potential risk. First trimester: unknown risk. Second/third trimesters: unknown risk.
It is not known whether bethanechol is excreted in human milk. Caution should be exercised when administered to a nursing woman. M/P ratio is unknown.
No data on excretion in human milk. M/P ratio unknown. Caution should be exercised; consider developmental benefits of breastfeeding vs. mother's need for drug.
No formal pharmacokinetic studies in pregnancy. Due to increased plasma volume and renal clearance, dose adjustments may be necessary but specific recommendations are lacking. Use lowest effective dose and monitor clinical response.
No established dosing guidelines for pregnancy. Pharmacokinetic changes in pregnancy may alter drug exposure, but no specific dose adjustments recommended due to lack of data. Use lowest effective dose if necessary.
DUVOID (bethanechol) is a cholinergic agonist used for urinary retention. Monitor for cholinergic crisis (excessive salivation, sweating, bradycardia). Administer on an empty stomach to reduce GI upset. Avoid in patients with asthma, hyperthyroidism, peptic ulcer disease, or epilepsy. Atropine is the antidote for overdose.
Cevimeline is a muscarinic agonist with higher affinity for M3 receptors, making it effective for xerostomia in Sjögren's syndrome. Avoid in patients with uncontrolled asthma, narrow-angle glaucoma, or iritis. Monitor for excessive sweating and bradycardia. Can be combined with pilocarpine but increase vagal tone risk.
Take this medication on an empty stomach, 1 hour before or 2 hours after meals.,Report any signs of excessive sweating, salivation, or bradycardia to your healthcare provider.,Avoid driving or operating machinery until you know how this drug affects you.,Do not stop taking this medication abruptly; consult your doctor for dose adjustments.,Keep a list of all medications you take and share with your healthcare provider.
Take with or without food, but taking after meals may reduce nausea.,Avoid driving or operating machinery if you experience blurred vision or dizziness.,Drink plenty of water to prevent dehydration from sweating.,Report symptoms like slow heart rate, chest pain, or difficulty breathing immediately.,Do not stop abruptly; consult your doctor for dose adjustments.
No interactions on record
"Cevimeline, a muscarinic cholinergic agonist, can decrease the metabolism of Betaxolol, a selective beta1-adrenergic receptor antagonist, by competitively inhibiting CYP2D6, a key enzyme responsible for Betaxolol's hepatic clearance. This pharmacokinetic interaction may lead to elevated plasma concentrations of Betaxolol, increasing its beta-blocking effects and potentially causing excessive bradycardia, hypotension, and bronchospasm, particularly in patients with pre-existing cardiac or respiratory conditions."
"Cevimeline, a muscarinic agonist used for xerostomia, can inhibit the metabolism of diphenhydramine by competitively blocking cytochrome P450 (CYP) 2D6 and 3A4 enzymes. This results in reduced clearance of diphenhydramine, leading to elevated plasma concentrations and increased risk of anticholinergic side effects such as sedation, confusion, dry mouth, blurred vision, and urinary retention. Clinically, patients may experience enhanced and prolonged central nervous system depression and anticholinergic toxicity."
"Bopindolol, a non-selective beta-adrenergic antagonist, may inhibit the bronchodilatory effects of cevimeline, a muscarinic agonist that stimulates salivary secretion partly via beta-adrenergic pathways. This can exacerbate cevimeline's parasympathomimetic adverse effects such as bradycardia, hypotension, and bronchoconstriction, particularly in patients with cardiovascular or respiratory comorbidities. Clinically, the combination may lead to increased incidence of symptomatic bradycardia and reduced therapeutic efficacy of cevimeline in managing xerostomia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DUVOID vs CEVIMELINE HYDROCHLORIDE, answered by our medical review team.
DUVOID is a Cholinergic Agonist that works by Selective alpha-1A adrenergic receptor antagonist; relaxes smooth muscle in the bladder neck and prostate, reducing outflow resistance.. CEVIMELINE HYDROCHLORIDE is a Cholinergic agonist (sialogogue) that works by Cevimeline is a muscarinic cholinergic agonist that binds to M1 and M3 receptors, stimulating salivary gland secretion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DUVOID and CEVIMELINE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DUVOID is: 100 mg orally three times daily.. The standard adult dose of CEVIMELINE HYDROCHLORIDE is: 30 mg orally three times daily. May increase to 60 mg three times daily if needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DUVOID and CEVIMELINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DUVOID is classified as Category C. DUVOID (bethanechol) is classified as FDA Pregnancy Category C. No adequate studies in pregnant women. Animal reproduction studies have not been conducted. Fetal risk cannot be rul. CEVIMELINE HYDROCHLORIDE is classified as Category C. Pregnancy Category C. In animal studies, cevimeline caused reduced fetal weight and increased skeletal variations at doses 0.1 times the maximum recommended human dose. No adequate. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.